BMS Archive

Fungi · Scientific monograph

Amanita muscaria

Fly Agaric

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Pharmacological isolation, GABA-A modulation, Neurological & Cognitive Research

Research overview

Historical use

One of the most culturally iconic mushrooms globally. Used in shamanic traditions across Siberia and northern Europe for millennia as an entheogen. Historical use by the Koryak, Chukchi, and other Siberian shamans; speculated to be the 'Soma' of the Rigveda (Gordon Wasson's hypothesis, contested). The active compounds ibotenic acid and muscimol are entirely distinct from the psilocybin found in Psilocybe species. Culturally associated with Christmas/Yule traditions in northern Europe.

Modern research context

Interest is primarily pharmacological and research-oriented. Muscimol is a potent, selective GABA-A receptor agonist and is reviewed among classic neuroscience compounds [2]. Chemistry, biology, toxicology, and ethnomycology have been comprehensively reviewed [1]. Ibotenic acid is a potent glutamate (NMDA/AMPA) receptor agonist used experimentally to create animal models of neurodegeneration [1]. Analytical characterisation of ibotenic acid, muscimol, and ergosterol content in A. muscaria hydrolysate preparations has been published [5]. Accidental poisoning cases are documented clinically [3]. Microdosing with A. muscaria extracts is a growing unregulated consumer trend studied via online community analysis [4]; clinical safety data are absent.

Adverse effects

TOXIC if consumed without preparation: nausea, vomiting, hypersalivation, sweating, miosis (muscarine — minor component). CNS effects: sedation, dissociation, confusion, delirium, ataxia (muscimol/ibotenic acid). Rarely fatal in adults; potentially fatal in children and small adults. Symptoms: cholinergic + anticholinergic + CNS-depressant syndrome. Ibotenic acid is neurotoxic.

Contraindications

Raw or unprepared Amanita muscaria must not be consumed therapeutically. Ibotenic acid is neurotoxic. CNS depressants — additive effect. Not suitable for self-administration. All use must be under controlled research conditions.

Clinical and phytochemical data

Used part

Cap (pileus) — pharmacological isolation of muscimol and ibotenic acid

Primary active compounds

  • Muscimol (3-hydroxy-5-aminomethyl-isoxazole — GABA-A agonist)

  • Ibotenic acid (alpha-amino-3-hydroxy-5-isoxazole-acetic acid — excitatory neurotoxin, decarboxylates to muscimol)

  • Muscarine (minor component — cholinergic agonist)

  • Muscazone

  • Stizolobic acid

Mechanism of action

Muscimol is a highly potent, selective GABA-A receptor agonist (structural analogue of GABA), producing sedation, anxiolysis, and psychedelic effects. Ibotenic acid is an NMDA receptor and mGluR agonist (excitotoxic at high doses); rapidly decarboxylated in vivo to muscimol. Muscimol also acts at cerebellar GABA-B receptors. Muscarine (minor component) activates mAChR (muscarinic acetylcholine receptors), contributing to cholinergic toxidrome symptoms.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Muscimol and ibotenic acid well absorbed orally. Ibotenic acid crosses the blood-brain barrier actively. Muscimol crosses BBB via facilitated transport.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Muscimol is water-soluble with moderate CNS penetration via passive diffusion; distributes to GABAergic neurons in cortex, cerebellum, and limbic system. Ibotenic acid is rapidly decarboxylated to muscimol in vivo. Muscimol is excreted largely unchanged in urine (~80%). Plasma half-life of muscimol approximately 3–5 hours.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ibotenic acid decarboxylated to muscimol (in vivo and during food preparation). Muscimol excreted largely unchanged (urinary excretion). Minimal hepatic metabolism.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Muscimol: primarily renal excretion unchanged (~20% of ingested dose recovered in urine — sufficient for psychoactive effects in individuals who consume recycled urine, a documented traditional practice in Siberian shamanism).

Safety and interactions

Drug interactions

CNS depressants (benzodiazepines, alcohol, barbiturates, opioids) — markedly additive CNS depression. Anticholinergic drugs — interaction with muscarine-mediated cholinergic effects. GABAergic drugs — additive GABA-A modulation.

Toxicity

Ibotenic acid: neurotoxic; hippocampal lesions demonstrated at high experimental doses. LD50 of ibotenic acid in rodents: ~38 mg/kg (IV), higher for oral. LD50 of muscimol: ~45 mg/kg (IV, rodents). Human fatalities from Amanita muscaria are rare (primarily in children or after massive ingestion) but documented. NOT safe for uncontrolled use.

Special precautions

Pregnancy

Contraindicated. Ibotenic acid is neurotoxic. Potential teratogenicity not fully characterised but neurotoxic mechanism is deeply concerning.

Lactation

Contraindicated. Muscimol excreted in urine; breast milk excretion not characterised but highly plausible given CNS penetration.

Hepatic impairment

Minimal hepatic metabolism — less relevant. CNS/renal effects predominate. Avoid entirely.

Renal impairment

Muscimol excreted renally; reduced clearance in renal impairment prolongs CNS toxicity. Avoid entirely.

Sources and references

  1. [1] - Michelot D., "Amanita muscaria: chemistry, biology, toxicology, and ethnomycology.", Mycol Res, 2003, PMID: 12747324
  2. [2] - Rivera-Illanes D., "Classics in Chemical Neuroscience: Muscimol.", ACS Chem Neurosci, 2024, PMID: 39254100
  3. [3] - Rampolli FI., "The Deceptive Mushroom: Accidental Amanita muscaria Poisoning.", Eur J Case Rep Intern Med, 2021, PMID: 33768066
  4. [4] - Hartwig J., "Exploring User Experiences with Amanita muscaria: A Thematic Analysis of Reddit Online Forum Discussions.", Subst Use Misuse, 2025, PMID: 40057818
  5. [5] - Dushkov A., "Analysis of the Ibotenic Acid, Muscimol, and Ergosterol Content of an Amanita Muscaria Hydrolysate.", Molecules, 2023, PMID: 37836667

Additional source links

Continue browsing